Cumberland Pharmaceuticals (CPIX) Q3 2026 earnings summary

Executive summary

• Q3 2026 was the first full quarter after the July 1 transaction, which transferred commercial brands and operations to Apotex’s U.S. branded business for $100M at closing.

• Strategy shifted to clinical development, prioritizing late-stage programs led by ifetroban and exploring commercialization and partnering alternatives.

• Q3 net income of $77.78M included an $81.09M disposal gain; transaction proceeds strengthened liquidity and enabled a $22M special dividend.

Financial highlights

• Q3 total revenue was $2.16M, including $1.95M of transition services revenue; operating loss was $1.94M.

• Q3 net income was $77.78M, including an $81.09M disposal gain; continuing-operations net loss was $1.12M.

• 9M 2026 revenue was $2.49M and net income was $70.22M, including the $81.09M disposal gain.

• At September 30, cash and equivalents were $80.58M, total assets $113.78M, liabilities $41.60M and equity $72.18M.

• Q3 interest income was $0.8M from investment of transaction proceeds.

Outlook and guidance

• Ifetroban DMD NDA preparation follows a pre-NDA FDA meeting; rolling review allows completed sections to be submitted ahead of the full filing.

• NDA support includes FIGHT DMD and open-label extension data, preclinical and manufacturing information, and a safety database covering over 1,400 subjects across ~30 studies.

• Systemic sclerosis plans include filing the clinical study report with FDA and completing biomarker and cardiac imaging analyses to guide further development.

• Remaining cash is projected to fund operations for over five years; interim efficacy results are the next IPF trial milestone.